Biotech/Pharma Docket

By James DeGiulio — Teva's Patents Covering Copaxone Upheld in Infringement Suit Mylan failed in its efforts to dismiss Teva's patent suit over the multiple-sclerosis drug Copaxone when the patents directed to the active pharmaceutical ingredient (API) in the drug, glatiramer acetate, were upheld as valid. In September 2008, Teva brought suit in the Southern District of New York against Sandoz, and in 2009 against Mylan, after both companies filed Abbreviated New Drug Applications (ANDAs) for Copaxone (see "Court Report," September 7, 2008 and November 8, 2009). Teva asserted four patents in its infringement suits: U.S. Patent Nos. 7,199,098, 6,939,539,…

Read more detail on Recent Intellectual Property Law Posts –

Legal notice about the Biotech/Pharma Docket rubric : Hukuki Net Legal News is not responsible for the privacy statements or other content from Web sites outside of the site. Please refer the progenitor link to check the legal entity of this resource hereinabove.

Do you need High Quality Legal documents or forms related to Biotech/Pharma Docket?

This entry was posted in Intellectual Property and tagged , . Bookmark the permalink.

Leave a Reply